Toll-like receptor 7
6
MENTIONS
2
EPISODES
1
PODCASTS
Search complete. 6 mentions across 2 episodes found for "Toll-like receptor 7".
Sep 30, 2026
Maria Dall'EraGUEST
Yes, BDCA2 is a C-type lectin that's expressed on the surface of the plasmacytoid dendritic cell.
Maria Dall'EraGUEST
And, you know, in the natural state, it serves as a down regulator of signaling through TLR7 and 9, which are in the endosome of the PDC.
Maria Dall'EraGUEST
And it also acts in its natural state for antigen capture because we know that dendritic cells, of course, are very important in antigen presentation to initiate the adaptive immune response.
Maria Dall'EraGUEST
And, you know, so thus it's a very interesting target because in ligating BDCA2, as I just mentioned, you will see a down regulation and inhibition of signaling through TLR7 and 9, which are very important in nucleic acid sensing, both RNA and DNA.
Maria Dall'EraGUEST
which then lead to the production of type 1 interferon and a variety of other pro-inflammatory cytokines.
Maria Dall'EraGUEST
So by harnessing this natural kind of inhibitory mechanism through binding to BDCA2, the idea here is to basically inhibit signaling through these very important toll-like receptors 7 and 9.
Maria Dall'EraGUEST
The FC region binds to FC gamma receptor 2A, which is on the surface of the PDC as well.
Maria Dall'EraGUEST
And then the whole antibody is basically internalized into the PDC.
Maria Dall'EraHOST
We already mentioned lidophilumab, which targets the BDCA2 antigen.
Maria Dall'EraHOST
We also have empatoran, which is inhibitor of TLR7 and 8.
Maria Dall'EraHOST
Each of these therapies is targets the type 1 interferon pathway in different ways and at different points in that pathway.
Maria Dall'EraHOST
And I'm wondering how thinking about these various therapies influences your decision making in terms of which therapy you may or may not choose for a specific patient that you're seeing in the clinic.